keyword
MENU ▼
Read by QxMD icon Read
search

nodular lymphocyte predominant hodgkin disease

keyword
https://www.readbyqxmd.com/read/29230339/nodular-lymphocyte-predominant-hodgkin-lymphoma-of-the-ileum
#1
Aruna Rangan, Sarah W Grahn, Andrew L Feldman
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma derived from germinal center B lymphocytes that typically presents with localized lymph node involvement and can mimic a variety of both reactive and other neoplastic conditions. Extranodal involvement is uncommon in NLPHL and typically occurs in the context of previously documented or synchronous nodal disease. Involvement of the gastrointestinal tract is exceedingly rare. Here, we present the first case to our knowledge of NLPHL involving the ileum that was discovered incidentally on routine screening colonoscopy in an asymptomatic patient...
2017: Case Reports in Pathology
https://www.readbyqxmd.com/read/29222274/nodular-lymphocyte-predominant-hodgkin-lymphoma-a-unique-disease-deserving-unique-management
#2
REVIEW
Dennis A Eichenauer, Andreas Engert
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with an incidence of 0.1 to 0.2/100 000/y. Compared with the more common subtypes of classical Hodgkin lymphoma, NLPHL is characterized by distinct pathological and clinical features. Histologically, the disease-defining lymphocyte predominant cells consistently express CD20 but lack CD30. Clinically, NLPHL mostly has a rather indolent course, and patients usually are diagnosed in early stages. The prognosis of early-stage NLPHL is excellent, with progression-free survival and overall survival rates exceeding 90% after involved-field radiotherapy (IF-RT) alone (stage IA) or combined modality treatment consisting of a brief chemotherapy with 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy followed by IF-RT (early stages other than stage IA)...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29051078/the-role-of-radiation-in-all-stages-of-nodular-lymphocytic-predominant-hodgkin-lymphoma
#3
Bismarck Odei, Dustin Boothe, Jonathan Frandsen, Matthew M Poppe, David K Gaffney
BACKGROUND: The goal of this study was to assess the survival differences seen in early-stage and advanced-stage nodular lymphocytic predominant Hodgkin lymphoma (NLPHL) based on treatment modality. PATIENTS AND METHODS: The National Cancer Database was queried to identify patients diagnosed with NLPHL between 2004 and 2012. Overall survival (OS) was determined using univariate and multivariate Cox regression analysis. Kaplan-Meier and log-rank analysis were used to estimate differences in OS between treatment groups...
September 23, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29034220/head-and-neck-lymphoma-in-an-iranian-population
#4
Nafiseh Shamloo, Alireza Ghannadan, Mahsa Jafari, Samane Ahmadi, Hamed Mortazavi, Maryam Baharvand
INTRODUCTION: This study is aimed to assess the prevalence and characteristics of head and neck lymphoma in a defined group of an Iranian population. MATERIALS AND METHODS: In this retrospective study, 126,450 biopsy reports from two referral Pathology Departments, (Tehran, the capital of Iran) were evaluated. In cases with head and neck lymphoma, other variables such as age, sex, specific location of lesions, and histopathological findings were recorded. Descriptive statistics were used to measure the prevalence and characteristics of head and neck lymphoma by means of SPSS soft ware, version 18...
September 2017: Iranian Journal of Otorhinolaryngology
https://www.readbyqxmd.com/read/28971503/high-dose-chemotherapy-and-autologous-stem-cell-transplantation-in-nodular-lymphocyte-predominant-hodgkin-lymphoma-a-retrospective-study-by-the-european-society-for-blood-and-marrow-transplantation-lymphoma-working-party
#5
Saad Akhtar, Silvia Montoto, Ariane Boumendil, Herve Finel, Tamas Masszi, Pavel Jindra, Damir Nemet, Stephan Fuhrmann, Yves Beguin, Luca Castagna, Felicetto Ferrara, Saveria Capria, Ram Malladi, Jose Maria Moraleda, Adrian Bloor, Hervé Ghesquières, Julia Meissner, Anna Sureda, Peter Dreger
Whilst autologous stem cell transplantation (auto-SCT) is considered standard of care for relapsed/refractory classical Hodgkin lymphoma, the role of auto-SCT in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is not well defined due to limited data. We report the first study on auto-SCT for NLPHL with a larger cohort. Eligible for this retrospective registry study were patients reported to the EBMT between 2003 and 2013, aged 18 or older with relapsed/refractory NLPHL who underwent first auto-SCT with disease chemosensitive to salvage therapy...
October 3, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28902084/children-and-adolescent-hodgkin-lymphoma-in-argentina-long-term-results-after-combined-abvd-and-restricted-radiotherapy
#6
Pedro A Zubizarreta, Elizabeth Alfaro, Myriam Guitter, Cristian Sanchez La Rosa, María L Galluzzo, Natalia Millán, Fernando Fiandrino, María S Felice
OBJECTIVE: Prospective analysis of clinical characteristics and long-term treatment results of a pediatric cohort with Hodgkin lymphoma (HL) treated in a single institution with ABVD and restricted radiotherapy (RT). PATIENTS AND METHODS: Between September 2000 and December 2015, 165 new consecutive assessable patients with HL were registered at our institution. Lymphocyte predominant nodular HL was excluded. Low risk (LR) patients were stage I and IIA (no bulky disease, <4 involved ganglionar areas and no lung hilar nodes), high risk (HR) was assigned to stage IV and any other stage with bulky mediastinum...
November 2017: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/28707314/nodular-lymphocyte-predominant-hodgkin-s-lymphoma-in-daily-practice-a-multicenter-experience
#7
Aliihsan Gemici, Ismet Aydogdu, Hatice Terzi, Mehmet Sencan, Alma Aslan, Ali Hakan Kaya, Mehmet Sinan Dal, Meltem Olga Akay, Mehmet Hilmi Dogu, Orhan Ayyildiz, Fahri Sahin, Gulsum Akgun Cagliyan, Mehmet Yilmaz, Zafer Gokgoz, Yusuf Bilen, Cengiz Demir, Omur Gokmen Sevindik, Serdal Korkmaz, Bulent Eser, Fevzi Altuntas
Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey. We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty-three patients were included in the study. Median age of patients was 37...
July 14, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28522441/encouraging-activity-for-r-chop-in-advanced-stage-nodular-lymphocyte-predominant-hodgkin-lymphoma
#8
Michelle A Fanale, Chan Yoon Cheah, Amy Rich, L Jeffrey Medeiros, Chao-Ming Lai, Yasuhiro Oki, Jorge E Romaguera, Luis E Fayad, F B Hagemeister, Felipe Samaniego, Maria A Rodriguez, Sattva S Neelapu, Hun J Lee, Loretta Nastoupil, Nathan H Fowler, Francesco Turturro, Jason R Westin, Michael L Wang, Peter McLaughlin, Chelsea C Pinnix, Sarah A Milgrom, Bouthaina Dabaja, Sandra B Horowitz, Anas Younes
Nodular lymphocyte Hodgkin lymphoma (NLPHL) is a rare disease for which the optimal therapy is unknown. We hypothesized that rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) could decrease rates of relapse and transformation. We retrospectively reviewed patients with NLPHL diagnosed between 1995 and 2015 confirmed by central pathologic review. Fifty-nine had sufficient treatment and follow-up data for analysis. We described progression-free survival (PFS), overall survival (OS), and histologic transformation according to treatment strategy and explored prognostic factors for PFS and OS...
July 27, 2017: Blood
https://www.readbyqxmd.com/read/27981925/comparison-of-presentation-and-outcome-in-100-pediatric-hodgkin-lymphoma-patients-treated-at-children-hospital-lahore-pakistan-and-royal-marsden-hospital-uk
#9
COMPARATIVE STUDY
Mahwish Faizan, Mary M Taj, Saadia Anwar, Nyla Asghar, Alia Ahmad, Donna Lancaster, Ayad Atra, Agha Shabbir Ali
OBJECTIVE: To compare differences in demographics and outcomes in childhood Hodgkin lymphoma (HL) presenting at the Children's Hospital Lahore (CHL), and Royal Marsden Hospital (RMH), UK. STUDY DESIGN: An observational comparative study. PLACE AND DURATION OF STUDY: From January 2011 to February 2012 at CH, Lahore and from October 2008 to February 2012 at RMH, UK. METHODOLOGY: Consecutive HL patients (50 from each hospital) were inducted...
November 2016: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/27888658/a-case-of-composite-classical-and-nodular-lymphocyte-predominant-hodgkin-lymphoma-with-progression-to-diffuse-large-b-cell-non-hodgkin-lymphoma-diagnostic-difficulty-in-fine-needle-aspiration-cytology
#10
Dilip K Das, Zafar A Sheikh, Mariam H Al-Shama'a, Bency John, Abdulla M S Alawi, Thamradeen A Junaid
A small percentage of nodular lymphocytic predominant Hodgkin lymphoma (NLPHL) progresses to diffuse large B-cell lymphoma (DLBCL). There have also been rare reports of gray zone lymphoma with features intermediate between classical Hodgkin lymphoma (CHL) and DLBCL. We report a very rare case of composite lymphoma (CHL and NLPHL) progressing to DLBCL, and highlight the diagnostic difficulty faced during its fine-needle aspiration (FNA) cytology diagnosis. A 65-year-old woman presented with a right axillary swelling which was subjected to FNA cytology...
March 2017: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/27644653/clinico-hematological-findings-for-classical-hodgkin-s-lymphoma-an-institutional-experience
#11
Sadia Sultan, Syed Mohammed Irfan, Saira Parveen, Saif Ali
BACKGROUND: Classical Hodgkin's lymphoma (cHL) is a B-cell lymphoid neoplasm characterized by a distinctive biological behavior with potentially curable disease characteristics. It is an uncommon hematological malignancy which primarily affects younger individuals. The rationale of this study was to determine its clinico-hematological profile along with stage strati cation in Pakistani patients. MATERIALS AND METHODS: In this descriptive study, adult patients with Hodgkin's lymphoma were enrolled from January 2010 to December 2014...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27496311/nodular-lymphocyte-predominant-hodgkin-lymphoma
#12
REVIEW
Kerry J Savage, Anja Mottok, Michelle Fanale
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma with distinct clinicopathologic features. It is typified by the presence of lymphocyte predominant (LP) cells, which are CD20(+) but CD15(-) and CD30(-) and are found scattered amongst small B lymphocytes arranged in a nodular pattern. Despite frequent and often late or multiple relapses, the prognosis of NLPHL is very favorable. There is an inherent risk of secondary aggressive non-Hodgkin lymphoma (NHL) and studies support that risk is highest in those with splenic involvement at presentation...
July 2016: Seminars in Hematology
https://www.readbyqxmd.com/read/27185197/phase-ii-trial-of-ofatumumab-plus-eshap-o-eshap-as-salvage-treatment-for-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-after-first-line-chemotherapy
#13
MULTICENTER STUDY
Carmen Martínez, Antonio Díaz-López, Mercedes Rodriguez-Calvillo, Ramón García-Sanz, María José Terol, Elena Pérez-Ceballos, Maria J Jiménez, Alberto Cantalapiedra, Eva Domingo-Domenech, María José Rodriguez, Antonia Sampol, Manuel Espeso, Francisco-Javier López, Javier Briones, Juan F García, Anna Sureda
The management of recurrent/refractory (R/R) Hodgkin lymphoma (HL) remains challenging. Previously published data have shown some efficacy of rituximab in this setting. The purpose of this phase II trial was to investigate the activity of ofatumumab in combination with etoposide, steroids, cytarabine and cisplatin (O-ESHAP) in 62 patients with R/R classical HL. Treatment consisted of ESHAP plus ofatumumab 1000 mg on days 1 and 8 of the first cycle and day 1 of the second and third cycles. O-ESHAP was well tolerated with only 3% of patients requiring treatment discontinuation because of adverse events...
September 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27133958/progressive-transformation-of-germinal-centers-single-center-experience-of-33-turkish-patients
#14
Melda Cömert Özkan, Nazan Özsan, Mine Hekimgil, Güray Saydam, Mahmut Töbü
Progressive transformation of germinal centers (PTGCs) is a benign disease of the lymph nodes that is rarely associated with Hodgkin disease. We reviewed the clinical and pathologic features of PTGCs and the relationship of PTGCs with lymphoid neoplasia in an adult population. The data from 33 patients who were diagnosed with PTCGs were retrospectively analyzed. Of the 33 PTGC patients, 48.5% were men and 51.5% were women, with a mean age of 43.8 years at diagnosis. Most of the enlarged and excised lymph nodes were cervical and axillary...
August 2016: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/27069706/papillary-thyroid-cancer-in-a-child-with-progressive-transformation-of-germinal-centers
#15
Suresh Mohan, Bradley DeNardo, Dariusz Stachurski, Jennifer Greene Welch, Jan C Groblewski
Objectives. To describe the presentation and management of a child with Progressive Transformation of Germinal Centers (PTGC), an uncommon condition characterized by significant persistent lymphadenopathy, who developed papillary thyroid carcinoma and to explore and review potential links between PTGC and neoplastic processes in the head and neck. Methods. Case presentation and literature review are used. Results. A 10-year-old female presented with a right parotid mass and cervical lymphadenopathy. Multiple biopsies revealed PTGC without malignancy...
2016: Case Reports in Otolaryngology
https://www.readbyqxmd.com/read/27001163/hodgkin-lymphoma-2016-update-on-diagnosis-risk-stratification-and-management
#16
REVIEW
Stephen M Ansell
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 9,050 new patients annually and representing approximately 11.2% of all lymphomas in the United States. DIAGNOSIS: HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte-rich HL are subgroups under the designation of classical HL...
June 2016: American Journal of Hematology
https://www.readbyqxmd.com/read/26996288/relapsed-or-poorly-responsive-nodular-lymphocyte-predominant-hodgkin-lymphoma-in-children-and-adolescents-a-report-from-the-united-kingdom-s-children-s-cancer-and-leukaemia-study-group
#17
Ananth G Shankar, Amy A Kirkwood, Sarita Depani, Eleonora Bianchi, Janis Hayward, Alan D Ramsay, Georgina W Hall
There is a paucity of data on the treatment outcome in children with relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma (nLPHL). This retrospective report evaluates the treatment outcome in a national cohort of children with relapsed or poorly responsive nLPHL. A total of 37 patients, 22 with relapsed and 15 with poorly responding disease, are the subjects of this report. Of the 22 patients with relapsed nLPHL, 11 had relapsed after primary excision biopsy, 10 after chemotherapy and 1 after chemotherapy and involved field radiotherapy...
May 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/26837698/large-b-cell-transformation-in-nodular-lymphocyte-predominant-hodgkin-lymphoma-40-year-experience-from-a-single-institution
#18
Saad Sirop Kenderian, Thomas M Habermann, William R Macon, Kay M Ristow, Stephen M Ansell, Joseph P Colgan, Patrick B Johnston, David J Inwards, Svetomir N Markovic, Ivana N Micallef, Carrie A Thompson, Luis F Porrata, James A Martenson, Thomas E Witzig, Grzegorz S Nowakowski
A number of reports have shown a propensity of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) to transform into diffuse large B-cell lymphoma (DLBCL). Long-term data on the incidence and outcomes of transformed NLPHL are lacking. A comprehensive analysis of the actively maintained Mayo Clinic Lymphoma Database was performed. Between 1970 and 2011, 222 consecutive adult patients with new untreated NLPHL were identified. Median age at diagnosis was 40 years, and 146 (66%) were males. The median follow-up was 16 years...
April 21, 2016: Blood
https://www.readbyqxmd.com/read/26732883/a-20-year-population-based-study-on-the-epidemiology-clinical-features-treatment-and-outcome-of-nodular-lymphocyte-predominant-hodgkin-lymphoma
#19
L Strobbe, L L F G Valke, I J Diets, M van den Brand, K Aben, J M M Raemaekers, K M Hebeda, J H J M van Krieken
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a subtype of Hodgkin lymphoma characterized by a unique clinical and histological presentation. Because of the rare nature of this disease, few large-scale studies are available. We conducted a cohort study in which patients were identified in the Netherlands Cancer Registry in the Southeast of the Netherlands between 1990 and 2010. Of these patients, we collected all clinical characteristics and re-reviewed pathologic material to confirm NLPHL diagnosis...
February 2016: Annals of Hematology
https://www.readbyqxmd.com/read/26541251/hodgkin-lymphoma-diagnosis-and-treatment
#20
REVIEW
Stephen M Ansell
Hodgkin lymphoma is a rare B-cell malignant neoplasm affecting approximately 9000 new patients annually. This disease represents approximately 11% of all lymphomas seen in the United States and comprises 2 discrete disease entities--classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Within the subcategorization of classical Hodgkin lymphoma are defined subgroups: nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte-rich Hodgkin lymphoma. Staging of this disease is essential for the choice of optimal therapy...
November 2015: Mayo Clinic Proceedings
keyword
keyword
90214
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"